Literature DB >> 25251693

Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: early postmarketing evidence.

Elaine H Morrato1, Joe Parks, Elizabeth J Campagna, Erik Muser, Deborah S K Thomas, Hai Fang, Dilesh Doshi.   

Abstract

AIM: To provide comparative effectiveness evidence for long-acting injectable paliperidone palmitate versus oral atypical antipsychotics. PATIENTS &
METHODS: We performed a retrospective, observational cohort study using patient claims data from Missouri Medicaid to compare the likelihood of emergency department (ED) visits and hospitalizations in the year following drug initiation using multivariable logistic regression.
RESULTS: Adjusted odds ratios (AOR) for ED visits (AOR: 0.63; 95% CI: 0.47-0.85) and hospitalizations (AOR: 0.85; 95% CI: 0.64-1.13) were lower in paliperidone palmitate patients, although hospitalizations did not achieve statistical significance. Sensitivity analyses examining mental health-related outcomes and using different analytic strategies for patient selection bias showed directionally similar beneficial effects but were not statistically significant.
CONCLUSION: Early evidence for paliperidone palmitate under real-world conditions is encouraging. However, caution should be taken until additional research substantiates the findings with greater certainty.

Entities:  

Keywords:  Medicaid; atypical antipsychotics; comparative effectiveness; emergency department visits; hospitalization; paliperidone palmitate

Mesh:

Substances:

Year:  2014        PMID: 25251693     DOI: 10.2217/cer.14.50

Source DB:  PubMed          Journal:  J Comp Eff Res        ISSN: 2042-6305            Impact factor:   1.744


  4 in total

1.  Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics.

Authors:  Jacqueline A Pesa; Erik Muser; Leslie B Montejano; David M Smith; Oren I Meyers
Journal:  Drugs Real World Outcomes       Date:  2015-10-13

2.  Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia.

Authors:  Dominic Pilon; Erik Muser; Patrick Lefebvre; Rhiannon Kamstra; Bruno Emond; Kruti Joshi
Journal:  BMC Psychiatry       Date:  2017-06-02       Impact factor: 3.630

3.  Effects of Paliperidone Palmitate on Healthcare Utilization and Costs for Patients with Schizophrenia: A Claim-based Mirror-image Study in South Korea.

Authors:  Dasom Lee; Boung Chul Lee; Soo-Hee Choi; Do-Hyung Kang; Duk-In Jon; Myung Hun Jung
Journal:  Clin Psychopharmacol Neurosci       Date:  2020-05-31       Impact factor: 2.582

Review 4.  Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review.

Authors:  Robin Emsley; Sanja Kilian
Journal:  Neuropsychiatr Dis Treat       Date:  2018-01-05       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.